Erectile Dysfunction - Pipeline Review, H2 2018

  • ID: 4592403
  • Report
  • 118 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Apricus Biosciences Inc
  • Biolab Farmaceutica Ltda
  • Biozeus Pharmaceutical SA
  • Futura Medical Plc
  • IntelGenx Corp
  • Mezzion Pharma Co Ltd
  • MORE
Erectile Dysfunction - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2018, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights:

This latest pipeline guide Erectile Dysfunction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 2, 6, 6, 1, 12, 2 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Apricus Biosciences Inc
  • Biolab Farmaceutica Ltda
  • Biozeus Pharmaceutical SA
  • Futura Medical Plc
  • IntelGenx Corp
  • Mezzion Pharma Co Ltd
  • MORE
Introduction

Report Coverage

Erectile Dysfunction - Overview

Erectile Dysfunction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Erectile Dysfunction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Erectile Dysfunction - Companies Involved in Therapeutics Development

Apricus Biosciences Inc

Aquestive Therapeutics Inc

Astellas Pharma Inc

Biolab Farmaceutica Ltda

Biopharm GmbH

Biozeus Pharmaceutical SA

Can-Fite BioPharma Ltd

Fabre-Kramer Pharmaceuticals Inc

Futura Medical Plc

Humanetics Corp

IntelGenx Corp

Ion Channel Innovations LLC

Karessa Pharma Holding AB

Mezzion Pharma Co Ltd

Mitsubishi Tanabe Pharma Corp

N4 Pharma Plc

NAL Pharmaceuticals Ltd

Pharmicell Co Ltd

SK Chemicals Co Ltd

Suda Pharmaceuticals Ltd

XuanZhu Pharma Co Ltd

Yangtze River Pharmaceutical Group

Erectile Dysfunction - Drug Profiles

(finasteride + tadalafil) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alprostadil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-185 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avanafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BZ-371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-ED - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FKK-01PD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPED-2015 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

libiguins - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MED-2002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MED-2005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirabegron ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pVAX-hSlo - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PDE5 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUD-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-6932 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tadalafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TF-0092 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPN-729 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TR-399 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

udenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vardenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-5849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Yonkenafil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Erectile Dysfunction - Dormant Projects

Erectile Dysfunction - Discontinued Products

Erectile Dysfunction - Product Development Milestones

Featured News & Press Releases

Jun 26, 2018: Initiator Pharma announces MHRA approval for clinical trial

Jun 19, 2018: iX Biopharma Obtains Approval and Registration of Wafesil for the Treatment of Male Erectile Dysfunction in Australia

Jun 04, 2018: Initiator Pharma selects Clinical Site

May 02, 2018: Best in Class Erectile Dysfunction Drug - DRGT announces dose escalation study results of its Super-Tadalafil DRGT-

Jan 22, 2018: Initiator Pharma successfully completes the preclinical development of its Erectile Dysfunction drug candidate IPED2015 ahead of time

Jan 04, 2018: Potential Breakthrough Treatment for Erectile Dysfunction

Dec 15, 2017: Initiator Pharma reports positive results from the 28 days toxicology study in mini-pigs for its lead drug candidate IPED2

Nov 22, 2017: Initiator Pharma receives positive result from the toxicology and toxicokinetic studies for its lead drug candidate IPED2

Oct 31, 2017: Humanetics Presents Data on Potential Treatment to Prevent Erectile Dysfunction in Prostate Cancer Patients

Oct 26, 2017: Initiator Pharma initiates toxicology and toxicokinetic studies for its lead drug candidate IPED2

Oct 10, 2017: N4 Pharma: Sildenafil PCT Update

Sep 07, 2017: A busy summer is providing valuable and Positive Results from the first Maximum tolerated dose toxicology for drug Candidate IPED2

Aug 23, 2017: iX Biopharma Provides Update on PheoniX

Jul 27, 2017: N4 Pharma: Filing of Patents and Sildenafil Update

Jul 27, 2017: N4 Pharma: Update on Sildenafil clinical plans

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Erectile Dysfunction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2018

Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, H2 2018

Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H2 2018

Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H2 2018

Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2018

Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, H2 2018

Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2018

Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2018

Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2018

Erectile Dysfunction - Pipeline by Humanetics Corp, H2 2018

Erectile Dysfunction - Pipeline by IntelGenx Corp, H2 2018

Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H2 2018

Erectile Dysfunction - Pipeline by Karessa Pharma Holding AB, H2 2018

Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H2 2018

Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Erectile Dysfunction - Pipeline by N4 Pharma Plc, H2 2018

Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H2 2018

Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H2 2018

Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H2 2018

Erectile Dysfunction - Pipeline by Suda Pharmaceuticals Ltd, H2 2018

Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H2 2018

Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H2 2018

Erectile Dysfunction - Dormant Projects, H2 2018

Erectile Dysfunction - Dormant Projects, H2 2018 (Contd..1), H2 2018

Erectile Dysfunction - Dormant Projects, H2 2018 (Contd..2), H2 2018

Erectile Dysfunction - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Erectile Dysfunction, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Apricus Biosciences Inc
  • Aquestive Therapeutics Inc
  • Astellas Pharma Inc
  • Biolab Farmaceutica Ltda
  • Biopharm GmbH
  • Biozeus Pharmaceutical SA
  • Can-Fite BioPharma Ltd
  • Fabre-Kramer Pharmaceuticals Inc
  • Futura Medical Plc
  • Humanetics Corp
  • IntelGenx Corp
  • Ion Channel Innovations LLC
  • Karessa Pharma Holding AB
  • Mezzion Pharma Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • N4 Pharma Plc
  • NAL Pharmaceuticals Ltd
  • Pharmicell Co Ltd
  • SK Chemicals Co Ltd
  • Suda Pharmaceuticals Ltd
  • XuanZhu Pharma Co Ltd
  • Yangtze River Pharmaceutical Group
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll